Zealand Pharma A/S/€ZEAL
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company focused on the discovery, design, and development of innovative peptide-based medicines. The company is headquartered in Copenhagen, Denmark, and operates in the pharmaceutical industry. Zealand Pharma's portfolio includes several marketed products and a robust pipeline addressing gastrointestinal, metabolic, and other specialty disease areas. Notably, their therapeutic offerings include dasiglucagon for severe hypoglycemia and other proprietary peptides. The company leverages its unique peptide platform to enhance drug discovery and development processes, aiming to deliver targeted treatments with potentially improved safety and efficacy profiles.
Ticker
€ZEAL
Sector
Primary listing
XGAT
Employees
424
Headquarters
Søborg, Denmark
Website
ZEAL Metrics
BasicAdvanced
€4B
4.59
€12.55
0.60
-
Price and volume
Market cap
€4B
Beta
0.6
52-week high
€124.64
52-week low
€41.44
Average daily volume
2.4K
Financial strength
Current ratio
15.092
Quick ratio
15.083
Long term debt to equity
2.431
Total debt to equity
2.543
Interest coverage (TTM)
224.24%
Profitability
EBITDA (TTM)
964.013
Gross margin (TTM)
100.06%
Net profit margin (TTM)
73.34%
Operating margin (TTM)
78.88%
Effective tax rate (TTM)
7.40%
Revenue per employee (TTM)
€2,879,230
Management effectiveness
Return on assets (TTM)
32.86%
Return on equity (TTM)
53.44%
Valuation
Price to earnings (TTM)
4.594
Price to revenue (TTM)
3.34
Price to book
1.93
Price to tangible book (TTM)
1.93
Price to free cash flow (TTM)
4.045
Free cash flow yield (TTM)
24.72%
Free cash flow per share (TTM)
14.256
Growth
Revenue change (TTM)
2,375.69%
Earnings per share change (TTM)
-892.73%
3-year revenue growth (CAGR)
344.16%
10-year revenue growth (CAGR)
61.01%
3-year earnings per share growth (CAGR)
50.65%
10-year earnings per share growth (CAGR)
28.12%
Bulls say / Bears say
The $5.3 billion licensing agreement with Roche for petrelintide, featuring a $1.65 billion upfront payment, improves Zealand’s cash position and demonstrates confidence in its peptide drug pipeline (Reuters).
Phase II results for survodutide showed side effects in line with leading GLP-1 injectables, supporting plans to start global Phase III trials with regulator input (Reuters).
Naming Utpal Singh, a former Eli Lilly executive, as chief scientific officer strengthens Zealand’s leadership team and increases its ability to advance peptide-based therapies (Financial Times).
Early petrelintide trials showed less weight loss compared to GLP-1 drugs, casting doubt on its ability to compete in the obesity market (Financial Times).
The obesity drug market is led by Novo Nordisk and Eli Lilly, both of which have a major lead in expertise, production, and market share, increasing competitive pressure on Zealand’s late-stage drugs (Financial Times).
Even in key U.S. and European markets, Zealand will receive only half of the profits from petrelintide sales due to its 50/50 profit-share agreement with Roche, limiting potential revenue growth (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zealand Pharma A/S stock?
Zealand Pharma A/S (ZEAL) has a market cap of €4B as of September 16, 2025.
What is the P/E ratio for Zealand Pharma A/S stock?
The price to earnings (P/E) ratio for Zealand Pharma A/S (ZEAL) stock is 4.59 as of September 16, 2025.
Does Zealand Pharma A/S stock pay dividends?
No, Zealand Pharma A/S (ZEAL) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Zealand Pharma A/S dividend payment date?
Zealand Pharma A/S (ZEAL) stock does not pay dividends to its shareholders.
What is the beta indicator for Zealand Pharma A/S?
Zealand Pharma A/S (ZEAL) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.